| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population | Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU ; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. | Journal of the Formosan Medical Association | 31 | ||
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population | Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; CHUN-JEN LIU ; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. | Journal of the Formosan Medical Association | 29 | ||
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population | Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L. | Journal of the Formosan Medical Association | 27 | ||
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population | Yu M.-L.; PEI-JER CHEN ; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. | Journal of the Formosan Medical Association | 27 | ||
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations | Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; CHUN-JEN LIU ; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. | Journal of the Formosan Medical Association | 32 | ||
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations | Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; CHEN-HUA LIU ; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. | Journal of the Formosan Medical Association | 38 | ||
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations | Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L. | Journal of the Formosan Medical Association | 38 | ||
| 2020 | 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations | Yu M.-L.; PEI-JER CHEN ; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; Liu C.-J.; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. | Journal of the Formosan Medical Association | 38 | ||
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | CHUN-JEN LIU ; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | World Journal of Gastroenterology | 43 | ||
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Liu C.-J.; Chang J.; PO-HUANG LEE ; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | World Journal of Gastroenterology | 43 | ||
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; REY-HENG HU ; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | World Journal of Gastroenterology | 41 | 43 | |
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; MING-CHIH HO ; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | World Journal of Gastroenterology | 41 | 43 | |
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN | World Journal of Gastroenterology | 43 | ||
| 2016 | All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study | JIA-HORNG KAO ; Lee Y.-J.; Heo J.; Ahn S.-H.; Lim Y.-S.; Peng C.-Y.; Chang T.-T.; Torbeyns A.; Hughes E.; Bhore R.; Noviello S. | Liver International | 24 | ||
| 2014 | All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study | Manns M.; Pol S.; Jacobson I.M.; Marcellin P.; Gordon S.C.; Peng C.-Y.; Chang T.-T.; Everson G.T.; Heo J.; Gerken G.; Yoffe B.; Towner W.J.; Bourliere M.; Metivier S.; Chu C.-J.; Sievert W.; Bronowicki J.-P.; Thabut D.; Lee Y.-J.; JIA-HORNG KAO ; McPhee F.; Kopit J.; Mendez P.; Linaberry M.; Hughes E.; Noviello S. | The Lancet | 274 | ||
| 2008 | Baicalein attenuates intimal hyperplasia after rat carotid balloon injury through arresting cell-cycle progression and inhibiting ERK, Akt, and NF-κB activity in vascular smooth-muscle cells | Peng C.-Y.; Pan S.-L.; Huang Y.-W.; JIH-HWA GUH ; Chang Y.-L.; Teng C.-M. | Naunyn-Schmiedeberg's Archives of Pharmacology | 39 | 37 | |
| 2020 | Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy | Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; CHEN-HUA LIU ; Chen P.-J.; Chen D.-S.; Kao J.-H. | Liver Cancer | 7 | ||
| 2020 | Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy | Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; CHUN-JEN LIU ; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. | Liver Cancer | 7 | ||
| 2020 | Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy | Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO | Liver Cancer | 7 | ||
| 2020 | Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy | Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; Liu C.-J.; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; PEI-JER CHEN ; Chen D.-S.; Kao J.-H. | Liver Cancer | 7 |
